國新健康(000503.SZ)業績快報:2020年度淨虧損2.43億元
格隆匯 4 月 13日丨國新健康(000503.SZ)發佈2020年度業績快報,實現營業總收入2.07億元,同比增長59.62%;利潤總額-2.43億元;歸屬於上市公司股東的淨利潤-2.43億元,上年度為淨利潤1742.78萬元;基本每股虧損0.2699元。
報吿期內,受貫穿全年的新冠疫情及技術、市場環境的影響,公司基於謹慎性考慮,依據估值結果,計提無形資產減值準備約3474萬元。此外,報吿期內,公司參股企業受行業政策等的影響,經營業績下滑,股權出現明顯減值跡象,依據估值結果,計提長期股權投資減值準備約6462萬元。減值金額合計約1億元。
公司於2019年9月29日與中國國新基金管理有限公司簽署協議,購買其持有的神州博睿99.01%合夥份額,交易價格為3.76億元。公司與中國國新基金管理有限公司的實際控制人同為中國國新控股有限責任公司,此次交易事項構成同一控制下企業合併,並於2020年6月完成工商變更。公司按照企業會計準則要求對合並報表進行追溯調整,導致期初歸屬於上市公司股東的所有者權益增加3.75億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.